Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT02170571 ·Status: COMPLETED ·Phase: PHASE1

Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

NCT00099450 ·Status: COMPLETED ·Phase: PHASE1

A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement

NCT06985615 ·Status: RECRUITING ·Phase: PHASE1

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

NCT01529294 ·Status: COMPLETED ·Phase: PHASE1

PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers

NCT02121860 ·Status: COMPLETED ·Phase: PHASE1

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

NCT04116476 ·Status: COMPLETED ·Phase: PHASE1

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

NCT02256033 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment

NCT01594957 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers

NCT02533102 ·Status: COMPLETED ·Phase: PHASE1

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

NCT01429337 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects

NCT02264054 ·Status: COMPLETED ·Phase: PHASE1

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

NCT04166942 ·Status: COMPLETED ·Phase: PHASE1

Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

NCT04322253 ·Status: TERMINATED ·Phase: PHASE1

A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838

NCT01356550 ·Status: COMPLETED ·Phase: PHASE1

A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants

NCT04493255 ·Status: COMPLETED ·Phase: PHASE1

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine

NCT00424671 ·Status: COMPLETED ·Phase: PHASE1

A Retrospective Study on Drug Induced Liver Injury in China

NCT02407964 ·Status: COMPLETED

Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction

NCT02754219 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

NCT00418626 ·Status: COMPLETED ·Phase: PHASE1

STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study

NCT01181505 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects

NCT07027982 ·Status: COMPLETED ·Phase: PHASE1

HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects

NCT04252417 ·Status: TERMINATED ·Phase: PHASE1

Explore the Performance of IntelliCap.

NCT02025348 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

NCT04276662 ·Status: COMPLETED ·Phase: PHASE1